Sputnik developers propose to investigate Covid-19 vaccines

The two-dose Sputnik V vaccine was the world’s first registered vaccine against Covid-19 and was also the first inoculant based on a heterogeneous booster or ‘vaccine combination’ approach that uses human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component, they specified in the text.

“This approach induces stronger immunity compared to vaccines which use the same delivery mechanism for both injections.”they added.

Meanwhile, the single dose Sputnik Light vaccine is the first component (recombinant human adenovirus 26 (rAd26) serotype) of the Sputnik V vaccine.

They also pointed out that “The Fund wishes to expand the knowledge of Russian and international scientists, as well as promote public awareness of real-world data on the safety and efficacy of Sputnik V, Sputnik Light and other vaccines..

In January 2021, RDIF and the Gamaleya Center established the International Scientific Advisory Board on the Sputnik V Vaccine, which brought together leading scientists in virology, microbiology and immunology from Argentina, Great Britain, Croatia, France, Germany, India, Sweden, United States. and Russia.

Studies based on the analysis of the use of the Sputnik V and Sputnik Light vaccines have been published in leading international peer-reviewed medical journals: The Lancet, EClinical Medicine (published by The Lancet), Vaccines and Cell Reports Medicine.